Video

Blake A. Morrison Discusses the Excitement in Myeloma Research

Author(s):

Blake A. Morrison

Blake A. Morrison discusses the recent excitement in myeloma research.

Blake A. Morrison, vice president, Medical and Scientific Affairs, Multiple Myeloma Research Foundation, discusses the recent excitement in myeloma research.

Morrison touches on the approvals of Empliciti (elotuzumab), Ninlaro (ixazomib) and Darzalex (daratumumab), as well as the research into CAR T cell immunotherapy.

Read more of our coverage from the 2015 ASH Annual Meeting

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Valerie Lee discussed emerging targeted therapies and personalized medicine approaches that are showing promise for those with gastrointestinal cancer.
Image of doctor.
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Related Content
Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles: © stock.adobe.com
April 4th 2025

Understanding the Use of Bispecific Antibodies in Multiple Myeloma

Ryan Scott
Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
image of dr. Lillian Siu.
April 3rd 2025

Breaking Down Early Signs and Symptoms of Head and Neck Cancer

Dr Lillian Siu
April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Illustration of cells.
March 27th 2025

Quadruplet Regimen Preferable to Triplets in Multiple Myeloma

Alex Biese
Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.
Illustration of blood cells.
March 26th 2025

Communication is Key When Transitioning Multiple Myeloma Care

Alex Biese
A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient Multiple Myeloma Summit.